Salarius Pharmaceuticals ... (SLRX)
2.48
-0.16 (-6.06%)
At close: Jan 15, 2025, 12:29 PM
undefined% (undefined)
| Bid | 2.47 |
| Market Cap | 3.57M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -5.14 |
| PE Ratio (ttm) | -0.48 |
| Forward PE | n/a |
| Analyst | n/a |
| Ask | 2.54 |
| Volume | 404,575 |
| Avg. Volume (20D) | 2,219,100 |
| Open | 2.63 |
| Previous Close | 2.64 |
| Day's Range | 2.29 - 2.64 |
| 52-Week Range | 1.22 - 7.20 |
| Beta | undefined |
About SLRX
Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing epigenetic-based cancer treatments. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a small molecular protein degrader for the treatment of hematological and solid tumors. It has a strategi...
Industry Biotechnology
Sector Healthcare
IPO Date Jan 29, 2015
Employees 2
Stock Exchange NASDAQ
Ticker Symbol SLRX
Website https://www.salariuspharma.com
2 days ago ·
Source
+133.76%
Salarius Pharmaceuticals shares are trading higher...
Unlock content with
Pro Subscription
9 months ago ·
Source
+5.98%
Salarius Pharmaceuticals shares are trading higher after the company reported Q4 financial results.
